- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00586911
Betaine in Patients With Nonalcoholic Steatohepatitis
April 6, 2015 updated by: Mayo Clinic
A Randomized, Placebo-Controlled Trial of Betaine in Patients With Nonalcoholic Steatohepatitis (NASH)
To assess the safety and efficacy of betaine in patients with NASH on markers of disease severity such as liver histology, liver biochemistries, and health related quality of life.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida at Gainesville
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult males or females, age 18 - 70 (inclusive) with NASH.
- Abnormal aminotransferase levels (1.5x normal) on at least two occasions at less three months apart.
- Histologic evidence of steatohepatitis on liver biopsy performed within six months of entry.
- Absence of sustained alcohol ingestion (less than 20 g/d in women or 30 g/d in men).
- Compensated liver disease and blood cell counts within the following limits: Hb > 12 gr/dl, platelets > 120,000/mm3, and WBC > 3,000/mm3
- TSH (thyroid-stimulating hormone) within normal limits of testing laboratory.
- Appropriate exclusion of other liver disease such as viral, autoimmune and metabolic/hereditary liver disease.
- If a history of diabetes, a hemoglobin A1C < 10.0%.
- Alpha-fetoprotein in normal range (obtained within the previous year), or if greater than normal, the patient requires a negative ultrasound for hepatocellular carcinoma within prior 3 months.
- Sexually active female patients of childbearing potential must practice adequate contraception during the treatment period and for 6 months after discontinuation of therapy. A pregnancy test obtained at entry prior to the initiation of treatment must by negative. Female patients must not be breast-feeding.
- Sexually active male patients must practice acceptable methods of contraception during the treatment period and for 6 months after discontinuation of therapy.
- Written informed consent for participation in this study.
Exclusion Criteria:
- Treatment with any experimental drug for NASH, betaine, ursodeoxycholic acid (URSO), methionine, rosiglitazone, metformin, pioglitazone, or vitamin E within 3 months of enrollment or at time of pre-entry liver biopsy. (Patients with diabetes and on stable medical management for six months prior to entry and an anticipated stable program throughout the study will be eligible. Medications that may be used include insulin, biguanides, thiazolidnediones, metformin, and sulfonylureas. Patients with hyperlipidemia on a medical program for control of lipids who have had a change in drug treatment in the preceding six months or with anticipated changes in the year of the study will also be eligible.)
- Any cause for the liver disease based on patient history and biopsy (where applicable) other than NASH
- Evidence of decompensated liver disease such as history or presence of ascites, bleeding varices, spontaneous encephalopathy.
- Any known pre-existing medical condition that could interfere with the patient's participation in and completion of the study such as significant cardiovascular dysfunction or chronic obstructive pulmonary disease requiring specific therapy
- Pregnancy or breastfeeding.
- Unwillingness of patient and/or partner to use contraception during treatment.
- Previous malignant disease (other than non-melanoma skin cancer) in the previous two years.
- Substance abuse, such as alcohol, I.V. drugs and inhaled drugs.
- Any other conditions that in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with the patient participating in and completing the protocol.
- Lactose intolerant patient since placebo preparation contains lactose.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Identical Placebo
|
Placebo
|
Active Comparator: Cystadane
|
Betaine 20 mg a day or identical placebo for 1 year.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
changes in degree of steatosis, necroinflammatory activity and fibrosis in liver biopsy.
Time Frame: 1 year
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary end-points will be changes in liver test results and health related quality of life.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2003
Primary Completion (Actual)
June 1, 2006
Study Completion (Actual)
June 1, 2006
Study Registration Dates
First Submitted
December 21, 2007
First Submitted That Met QC Criteria
December 21, 2007
First Posted (Estimate)
January 7, 2008
Study Record Updates
Last Update Posted (Estimate)
April 8, 2015
Last Update Submitted That Met QC Criteria
April 6, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 458-00
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nonalcoholic Steatohepatitis
-
Duke UniversityCompletedLiver Diseases | Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis | Nonalcoholic Fatty LiverUnited States
-
Gilead SciencesCompletedNonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD)United States, New Zealand
-
National Institute of Diabetes and Digestive and...CompletedNonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD)United States
-
Polaris GroupRecruiting
-
Corcept TherapeuticsRecruitingNonalcoholic Steatohepatitis (NASH)United States
-
PerspectumRecruitingNASH - Nonalcoholic SteatohepatitisUnited States
-
Metacrine, Inc.Completed
-
Cascade Pharmaceuticals, IncLaboratory Corporation of AmericaCompletedNonalcoholic Steatohepatitis (NASH)United States
-
Poxel SACompletedNASH - Nonalcoholic SteatohepatitisUnited States
-
RWTH Aachen UniversityCompletedNASH - Nonalcoholic SteatohepatitisSweden, Austria, Germany
Clinical Trials on Cystadane
-
McGill University Health Centre/Research Institute...Children's Hospital and Medical Center, Omaha, NebraskaCompleted
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Orphan...CompletedHyperoxaluriaUnited States